Effects of Pioglitazone in Calcific Aortic Valve Disease

Inclusion Criteria: * Male or female adult ≥ 35 years of age at the time of rescruiting. * Subject has calcific aortic valve disease with mild to moderate aortic valve stenosis as defined by Doppler echocardiography results: Aortic Valve mean pressure gradient between 10-30 mmHg and Aortic Valve Area ≥ 1.2 and ≤ 2.0 cm2 on TTE within 2 weeks prior to randomization and Cardiac Compute Tomography (CT) test results: aortic valve calcium score (Agatston score) ≥ 200 AU at baseline cardiac CT within 1 month prior to randomization * Subject provides written informed consent prior to initiation of any study procedures. * Subject understands and agrees to comply with planned study procedures. Exclusion Criteria: * Subject has concomitant moderate or severe mitral or tricuspid valve disease. * Subject has left ventricular ejection fraction \< 50%. * Subject previous history of aortic valve surgery, pancreatitis, malignant tumor, drug or alcohol abuse. * Subjects whose alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \> 2.5 times the upper limit of normal range. * Subjects who cannot undergo Cardiac CT. * Pregnant or lactating women. * Consideration by the investigator, for safety reasons, that the subject is an unsuitable candidate to receive study treatment.